Scientific Advisory Committee on Cardiovascular Therapies

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

Contact: Bureau of Policy, Science and International Programs Enquiries

Nomination Call

Notice

Therapeutic Products Directorate
Holland Cross, Tower "B"
6th Floor, 1600 Scott Street
Address Locator 3106B
Ottawa, Ontario
K1A 0K9

Our file number: 09-116062-281

Nomination call for members - Scientific Advisory Committee on Cardiovascular Therapies

Health Canada is seeking nominations for members for the Scientific Advisory Committee on Cardiovascular Therapies (SAC-CvT). The SAC-CvT will provide timely scientific, technical and medical advice on the evaluation of safety and efficacy of drugs used for the treatment of cardiovascular disease, ailments and disorders as well as related policy issues. The Committee will also advise on post-marketing issues related to drugs used in this therapeutic area. The Committee's draft Terms of Reference is attached.

Health Canada is looking for expertise in the various clinical specialties treating cardiovascular disease as well as in the areas of basic and applied pharmaceutical/biological sciences and technologies, biostatistics/epidemiology, medical biochemistry, pharmacology, pharmacy, toxicology and patient interest groups. Individuals whose specialties cross over into cardiovascular medicine would be of great value to the Committee.

Tentatively, the first meeting of the Committee is expected to be held in late November 2009. Among the first items to be discussed will be validation and assessment of surrogate endpoints as well as a review of the common clinical endpoints used in cardiovascular trials. Consequently, nominations of specialists in those specific areas would be appreciated.

Members will be selected based on the required expertise, the individual's breadth of experience and his or her familiarity with committee work. Consideration will also be given to the candidate's ability to balance scientific rigour with practical considerations, regulatory requirements and international perspectives. Health Canada strives to maintain a balance of gender, regional and linguistic representation in its selection of members.

Committee members will be appointed by the Director General of the Therapeutic Products Directorate following a review of all nominations by a Health Canada selection committee. The appointed members will have to undergo government security clearance and provide a declaration of their Affiliations and Interests. As a condition of membership, a summary of this information will be prepared, and once approved by the member, it will be posted to Health Canada's Web site. All travel and accommodation expenses will be compensated according to the Treasury Board policies. Members must participate as volunteers in order to be eligible for indemnification under Treasury Board's Volunteer Policy.

The Health Products and Food Branch Guidance on Advisory Bodies is used as the guiding document for all advisory bodies.

Please provide by September 30, 2009, the names, telephone numbers and curriculum vitae of nominees who satisfy the selection criteria outlined above to:

Larissa Lefebvre
Office of Science, Bureau of Policy, Science and International Programs
Therapeutic Products Directorate
Health Canada
1600 Scott Street,
Address Locator 3102C3
Ottawa, Ontario
K1A 0K9

Telephone: (613) 941-5514
Fax: (613) 941-0535
Email: Larissa_Lefebvre@hc-sc.gc.ca

Please ensure that the nominee is advised and is willing to have their name put forward as a potential candidate for this Committee.